Oncology

NovoMedix gets NIH grant to advance NMX1 in TNBC

The National Heart, Lung, and Blood Institute division of the NIH has awarded biotechnology company NovoMedix a $2m Phase II SBIR grant to further the development of novel small molecules that protect patients with triple-negative breast cancer (TNBC) from the long-term cardiotoxic impacts of doxorubicin chemotherapy.

EMA grants orphan drug designation to Cornerstone Pharmaceuticals’ CPI-613 (devimistat)

Cornerstone Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer.

Inceptor Bio raises $37m from Series A to advance CAR-T lead programme

Biotechnology firm Inceptor Bio has raised $37m from Series A funding round that was led by Kineticos Ventures.

Proteros expands oncology collaboration with AstraZeneca

Proteros biostructures has expanded its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.

Moma Therapeutics completes funding for precision oncology programmes

Moma Therapeutics has completed a $150m Series B financing led by Goldman Sachs Asset Management for advancement of several precision oncology programmes to clinical trials.

InxMed raises funding to advance new cancer therapies

InxMed has raised $15m in Series B+ financing funded by Hyfinity Investments to advance new therapies for the treatment of drug-resistant cancers.

Sapience receives orphan designation for ST101 to treat advanced melanoma

Sapience Therapeutics has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead programme, ST101, to treat advanced melanoma for patients in stages IIB through IV.

Daiichi Sankyo, AstraZeneca’s ENHERTU gets BTD for HER2 Low Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has secured breakthrough therapy designation (BTD) in the US to treat adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer.

FDA accepts AstraZeneca’s BLA review for tremelimumab to treat HCC

The US Food and Drug Administration (FDA) has accepted for review AstraZeneca’s Biologics License Application (BLA) for tremelimumab to treat patients with unresectable hepatocellular carcinoma (HCC).